The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti-β2 Glycoprotein 1 and Anti-Cardiolipin Antibodies

about

The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti-β2 Glycoprotein 1 and Anti-Cardiolipin Antibodies

Item

http://www.wikidata.org/entity/Q58693759

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

The Clinical Performance of a ...... nd Anti-Cardiolipin Antibodies

@en

The Clinical Performance of a ...... nd Anti-Cardiolipin Antibodies

@nl

type

Item

label

The Clinical Performance of a ...... nd Anti-Cardiolipin Antibodies

@en

The Clinical Performance of a ...... nd Anti-Cardiolipin Antibodies

@nl

prefLabel

The Clinical Performance of a ...... nd Anti-Cardiolipin Antibodies

@en

The Clinical Performance of a ...... nd Anti-Cardiolipin Antibodies

@nl

P1476

The Clinical Performance of a ...... nd Anti-Cardiolipin Antibodies

@en

P2093

Hua Zhang

http://www.w3.org/2001/XMLSchema#string

Jiansuo Zhou

http://www.w3.org/2001/XMLSchema#string

Liyan Cui

http://www.w3.org/2001/XMLSchema#string

Tiancheng Wang

http://www.w3.org/2001/XMLSchema#string

Xiuzhu Hou

http://www.w3.org/2001/XMLSchema#string

P2860

Seronegative antiphospholipid syndrome

Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Diagnosis and classification of the antiphospholipid syndrome.

Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens.

Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs.

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.

Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome.

The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation.

Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies.

P304

6816-6822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12659/MSM.910369

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30256771

http://www.w3.org/2001/XMLSchema#string

P932

6180949

http://www.w3.org/2001/XMLSchema#string